Abstract
The Renal Insufficiency and Anticancer Medications (IRMA) study reported the high prevalence of renal insufficiency in cancer patients. In this special report, we focused on patients with lung cancer, emphasizing some specific findings in this population of patients. Data on patients with lung cancer who were in the IRMA study were analyzed. Renal function was calculated using Cockcroft–Gault and abbreviated Modification of Diet in Renal Disease (aMDRD) formulas to estimate the prevalence of renal insufficiency (RI) according to the KDOQI-KDIGO definition. Anticancer drugs were studied with regard to their potential renal toxicity and need for dosage adjustment. Of the 445 IRMA lung cancer patients, 14.4% had a serum creatinine (SCR) level ≥110 μmol/L. However, when they were assessed using the formulas, 62.1 and 55.9% had abnormal renal function. Of the 644 anticancer drug prescriptions, 67.5% required dose adjustments for RI or were drugs with no available data, and 78.3% of the patients received at least one such drug. Furthermore, 71.6% received potentially nephrotoxic drugs. Seventy percent of the patients had anemia but prevalence was not significantly associated with the existence of associated renal insufficiency. In the 445 IRMA patients with lung cancer, the prevalence of RI was high in spite of a normal SCR in most cases. Some anticancer drugs such as platinum salts may be nephrotoxic and need dosage adjustment. However, other important drugs such as gemcitabine do not require dose reduction and do not present with a high potential for nephrotoxicity. Lung cancer patients often present with anemia, which was not associated with the presence of RI.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Matas AJ, Simmons RL, Kjellstrand CM, Buselmeier TJ, Najarian JS (1975) Increased incidence of malignancy during chronic renal failure. Lancet 1:883–886. doi:10.1016/S0140-6736(75)91684-0
Sutherland GA, Glass J, Gabriel R (1977) Increased incidence of malignancy in chronic renal failure. Nephron 18:182–184. doi:10.1159/000130762
Cengiz K (2002) Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 33:121–126. doi:10.1023/A:1014489911153
Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY (1998) Serum creatinine levels in the US population: third national health and nutrition examination survey. Am J Kidney Dis 32:992–999. doi:10.1016/S0272-6386(98)70074-5
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G, Renal Insufficiency and Cancer Medications (IRMA) Study Group (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376–1384. doi:10.1002/cncr.22904
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2)(Suppl 1):S1–S266
Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100. doi:10.1111/j.1523-1755.2005.00365.x
Cockcroft DW, Gault MH (1976) Prediction of CrCl from serum creatinine. Nephron 16:31–41. doi:10.1159/000130554
Levey AS, Greene T, Kusek JW et al (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:0828 [abstract]
Aronoff GR, Berns JS, Brier ME et al (1999) Drug prescribing in renal failure. Dosing guidelines for adults, 4th edn. American College of Physicians—American Society of Internal Medicine, Philadelphia, PA
Launay-Vacher V, Karie S, Deray G (2005) GPR Anticancéreux. Guide de prescription des médicaments chez le patient insuffisant rénal, 3ème éd. Méditions International, France
Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, Pocock S, Negoita M, Moussa I, Stone GW, Moses JW, Leon MB, Dangas G (2005) Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 67:706–713. doi:10.1111/j.1523-1755.2005.67131.x
Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European society of clinical pharmacy special interest group on cancer care. Cancer Chemother Pharmacol 61(6):903–909 doi:10.1007/s00280-008-0711-0
McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, Li S, Wang C, Bakris G, McCullough PA, Collins AJ, Norris KC, Kidney Early Evaluation Program Investigators (2008) Prevalence and associations of anemia of CKD: kidney early evaluation program (KEEP) and national health and nutrition examination survey (NHANES) 1999–2004. Am J Kidney Dis 51(4)(Suppl 2):S46–S55. doi:10.1053/j.ajkd.2007.12.019
Acknowledgment
Under the direction of the IRMA Scientific Committee, the IRMA Study has been coordinated by ICAR, a National Medical Advisory Service on the interactions between drugs and the kidney (i.e., drug dosage adjustment, drug nephrotoxicity, drug-drug interactions with immunosuppressive therapies), located in the Department of Nephrology at Pitié-Salpêtrière Hospital in Paris, France. The authors are indebted to the physicians who took time from their busy work schedules to participate in the IRMA Study Group and to Roche France, thanks to whom ICAR services are available to French oncologists through an unrestricted educational grant. IRMA Scientific Committee (in alphabetical order): P. Beuzeboc, Paris; G. Deray, Paris; J. Gligorov, Paris; V. Launay-Vacher, Paris; J.-F. Morere, Paris; S. Oudard, Paris; X. Pourrat, Tours; I. Ray-Coquard, Lyon, J.-P. Spano, Paris. IRMA Study Group (in alphabetical order): Pr A. Adenis, Lille; Dr E. Banu, Paris; Dr P. Beuzeboc, Paris; Dr H. Boostandoost, Paris; Dr S. Clisant, Lille; Dr N. Colbert, Paris; Dr L-M. Dourthe, Metz; Dr D. Egret, Nantes; Dr J. Egreteau, Lorient; Dr J. Gligorov, Paris; Dr J-P. Guastalla, Lyon; Dr M-F. Jaeger, Metz; Dr F. Joly, Caen; Dr J. Ayllon, Paris; Dr C. Le Tourneau, Paris; Dr C.-B. Levache, Périgueux; Dr A. Lortholary, Nantes; Mr C. Maguire, Périgueux; Dr A. Monnier, Montbéliard; Pr J-F. Morere, Paris; Dr E. Ouahrani, Paris; Pr S. Oudard, Paris; Dr I. Ray-Coquard, Lyon; Pr O. Rixe, Paris; Dr E. Sevin, Caen; Dr L. Stefani, Grenoble, France.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
The IRMA study group is based in Department of Nephrology, Pitie Salpetriere Hospital, Paris, France.
Rights and permissions
About this article
Cite this article
Launay-Vacher, V., Etessami, R., Janus, N. et al. Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues. Lung 187, 69–74 (2009). https://doi.org/10.1007/s00408-008-9123-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-008-9123-5